What Researchers Did
This prospective pilot study investigated the efficacy and safety of repetitive hyperbaric oxygen therapy (HBOT) as an adjunctive treatment in 46 acute ischemic stroke patients who did not receive thrombolytic therapy.
What They Found
The HBOT group (n=16) showed significant improvements in both early and late outcomes (NIHSS scores) (P ≤ 0.001), while the control group (n=30) only showed significant improvement in early outcome (P = 0.004). Although there was no difference in early efficacy between groups (P = 0.140), the HBOT group demonstrated a statistically significant difference in NIHSS score changes at one month compared to the control group (P ≤ 0.001).
What This Means for Canadian Patients
This pilot study suggests that hyperbaric oxygen therapy could potentially be a safe and effective adjunctive treatment for Canadian patients experiencing acute ischemic stroke who are not candidates for thrombolysis. If confirmed by larger studies, HBOT might offer an additional therapeutic option to improve long-term recovery for these patients.
Canadian Relevance
This study was not conducted in Canada and does not have direct Canadian relevance in terms of its origin or participant demographics.
Study Limitations
A significant limitation of this study is its small sample size and pilot nature, which restricts the generalizability of the findings.